TICKERNERD
Menu
IDYAIDYAHealthcare · Biotechnology

IDYA Stock Forecast: IDEAYA Biosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$36
−1.04% on the day

The 15 Wall Street analysts covering IDEAYA Biosciences, Inc. hold a median 12-month price target of $51 — +40.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.5B
Ticker Nerd rank
80 / 100
Median analyst target
$51
Analysts covering
15
Total return, dividends reinvested
1W
−1.9%
1M
−1.0%
YTD
+5.0%
1Y
+49.0%
From 52W high
−10.4%
From 52W low
+55.2%
$23
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IDYA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IDEAYA Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Quality
93
Value
91
Momentum
87
Volatility
86
Accruals
43
Revisions
38
Issuance
29
Size
29

Growth (98): Sales and profits are climbing, and climbing faster than before.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Size (29): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IDYA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IDYA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26IDYAHigh $65Median $51Low $31

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $31Median $51High $65

The green dot is the last close — the median target sits +40.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Truist SecuritiesMaintainsBuy$63 → $59
5 Aug 2026WedbushMaintainsOutperform$58 → $60
7 July 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$53 → $48
7 July 2026Truist SecuritiesMaintainsBuy—
7 July 2026Truist SecuritiesMaintainsBuy$65 → $63
12 June 2026WedbushReiteratesOutperform—
2 June 2026WedbushReiteratesOutperform—
7 May 2026MizuhoMaintainsOutperform—
14 Apr 2026Goldman SachsMaintainsNeutral—
14 Apr 2026GuggenheimMaintainsBuy—
14 Apr 2026RBC CapitalMaintainsOutperform—
14 Apr 2026WedbushMaintainsOutperform—
14 Apr 2026Wells FargoMaintainsOverweight—
31 Mar 2026WedbushReiteratesOutperform—
19 Feb 2026CitigroupMaintainsBuy—
18 Feb 2026GuggenheimReiteratesBuy—
18 Feb 2026RBC CapitalReiteratesOutperform—
18 Feb 2026WedbushMaintainsOutperform—
21 Jan 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IDYA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IDYA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

IDEAYA Biosciences, Inc. (IDYA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−28.4×

Cheaper than 97% of US stocks

Price / sales
14.9×

Cheaper than 11% of US stocks

Price / book
3.4×

Cheaper than 31% of US stocks

EV / EBITDA
−12.6×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
35.0%

Higher than 81% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1380.7%

Higher than 5% of US stocks

Net margin
−74.8%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−16.2%

Higher than 32% of US stocks

Return on assets
−11.5%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IDYA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IDYAIDEAYA Biosciences, Inc.$3.5B
80
ABCLAbCellera Biologics, Inc.$3.4B
71
QUREUniQure NV$3.3B
54
MBXMBX Biosciences, Inc.$3.3B
35
ARQTArcutis Biotherapeutics, Inc.$3.2B
89
CLDXCelldex Therapeutics, Inc.$3.2B
31
ALMSAlumis, Inc.$3.2B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IDEAYA Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IDYA news & analysis

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 4 Aug 2026positive

IDEAYA Biosciences reported its second quarter 2026 financial results, noting that its registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma met its primary endpoint and that an NDA filing is underway with completion expected in H2 2026. The company also announced a clinical collaboration with Roche for IDE892 in combination with RG6505, plans to present updated Phase 1/2 data at ESMO, and reported about $1.24 billion in cash as of June 30, 2026, with unchanged cash runway guidance into 2030.

Why it matters — A successful primary endpoint in the registrational mUM trial, an ongoing NDA filing, a new Roche collaboration, and an extended cash runway are key clinical and financial milestones that a IDYA watcher would track closely.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 31 July 2026neutral

IDEAYA Biosciences announced that its Compensation Committee granted non-qualified stock options for an aggregate of 260,200 shares of common stock to fourteen newly hired employees, effective July 30, 2026.

Why it matters — These inducement grants signal that IDEAYA is expanding its workforce, which may be of interest to shareholders tracking the company's growth and talent acquisition.

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

PRNewsWire · 27 July 2026positive

IDEAYA Biosciences announced that IDE892, its MTA-cooperative PRMT5 inhibitor, has initiated Part 2 monotherapy expansion in the Phase 1/2 study for MTAP-deleted pancreatic and lung cancers, after clearing multiple dose cohorts and achieving projected efficacious target exposures.

Why it matters — This advancement moves IDE892 closer to potential clinical utility in MTAP-deleted cancers, which represent up to 40% of pancreatic and ~15% of non-small cell lung cancers, a significant addressable patient population.

FAQ

Frequently asked questions about IDYA stock

What is the IDYA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering IDEAYA Biosciences, Inc. have a median 12-month price target of $51, with estimates ranging from $31 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IDYA stock a buy right now?

Of the 15 analysts covering IDEAYA Biosciences, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IDEAYA Biosciences, Inc. 80 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IDYA?

As at 15 Aug 2026, IDEAYA Biosciences, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will IDYA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +40.5% from the last close, and Ticker Nerd's factor model ranks IDEAYA Biosciences, Inc. 80 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IDYA stock forecast for 2030?

No analyst covering IDEAYA Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IDYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $65 over the next 12 months.

How has IDYA stock performed over the past year?

IDEAYA Biosciences, Inc. returned +49.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IDEAYA Biosciences, Inc. do?

Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics.

What is the latest news on IDYA?

The most recent item we track (PRNewsWire, 4 Aug 2026): "IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update". IDEAYA Biosciences reported its second quarter 2026 financial results, noting that its registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma met its primary endpoint and that an NDA filing is underway with completion expected in H2 2026. The company also announced a clinical collaboration with Roche for IDE892 in combination with RG6505, plans to present updated Phase 1/2 data at ESMO, and reported about $1.24 billion in cash as of June 30, 2026, with unchanged cash runway guidance into 2030.

Company

About IDEAYA Biosciences, Inc.

Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2/3 clinical trials for cancers with GNAQ or GNA11 mutations; IDE397, a methionine adenosyltransferase 2a inhibitor in Phase 2 for solid tumors with MTAP deletions like non-small cell lung cancer and urothelial cancer; IDE849, a DLL3 antibody drug conjugate in Phase 1 for small cell lung cancer and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor in Phase 1 for high microsatellite instability tumors; IDE161, a poly ADP-ribose glycohydrolase inhibitor in Phase 1/2 for homologous recombination deficiency tumors; and IDE705, a Poly Theta Helicase inhibitor in Phase 1 for BRCA-mutated tumors. The company also advances preclinical programs such as IDE892, an MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 bispecific antibody drug conjugate; and IDE251, a KAT6/7 inhibitor, alongside research platforms like DECIPHER for synthetic lethality and INQUIRE for drug discovery enhancement. Ideaya Biosciences Inc. maintains strategic alliances with partners including GlaxoSmithKline, Pfizer, Gilead Sciences, Merck, and others. Incorporated in 2015 and headquartered in South San Francisco, California, it plays a key role in advancing precision oncology therapies.

CEO Mr. Yujiro S. Hata · 145 employees · United States · https://www.ideayabio.com